Science Corp. raises $230 million for blindness treatment implant devices

LootboxPhobia · 2026-03-06T01:48:57+00:00

Neural technology company Science Corp. successfully raised $230 million, with a valuation of $1.5 billion, becoming the second-largest brain implant device company after Neuralink. Investors have injected over $2 billion to advance brain-computer interface technology and assist patients with severe illnesses. The current device has not yet received long-term FDA approval and is limited to clinical trials.

LootboxPhobia

2026-03-06 01:48:57

Abstract generation in progress

Investing.com – Neural technology company Science Corp. has raised $230 million from investors to commercialize its blindness treatment implant devices and develop more advanced brain-machine interfaces.

According to Bloomberg, citing sources familiar with the matter, this funding round values Science at $1.5 billion (including new financing). This valuation makes it the second-largest brain implant device company after Elon Musk’s Neuralink. Science Corp. is also the second-highest funded company in this sector, with a total of $489 million raised so far.

In recent years, investors have poured over $2 billion into the six major brain implant companies in the United States. Similar companies in China are also growing under government support. These funds enable startups to build brain-computer interfaces to help patients with severe conditions, such as enabling paralyzed patients to control computers with their thoughts or restoring partial vision for the blind.

Currently, no devices have received FDA approval for long-term commercial use, so these devices are only available in clinical trials.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.